MBB Public Markets I LLC Acquires Shares of 14,209 Kenvue Inc. $KVUE

Key Points

• MBB Public Markets I LLC acquired 14,209 shares of Kenvue Inc. valued at approximately $341,000 in the first quarter, indicating institutional interest in the stock.
• Various hedge funds have adjusted their stakes in Kenvue, with Vanguard Group Inc. increasing its holdings by 4.9%, now owning over 229 million shares.
• Kenvue increased its quarterly dividend to $0.2075 per share, representing an annual yield of 4.5% despite a current dividend payout ratio of 112.16%.

MBB Public Markets I LLC acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,209 shares of the company's stock, valued at approximately $341,000.

Several other large investors have also added to or reduced their stakes in KVUE. Cary Street Partners Financial LLC bought a new position in Kenvue in the 4th quarter worth about $270,000. Captrust Financial Advisors boosted its stake in Kenvue by 16.4% in the 4th quarter. Captrust Financial Advisors now owns 62,803 shares of the company's stock worth $1,341,000 after purchasing an additional 8,826 shares during the period. Ensign Peak Advisors Inc boosted its stake in Kenvue by 9.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 169,137 shares of the company's stock worth $3,611,000 after purchasing an additional 14,322 shares during the period. Focus Partners Wealth boosted its stake in Kenvue by 18.1% in the 4th quarter. Focus Partners Wealth now owns 1,564,568 shares of the company's stock worth $33,404,000 after purchasing an additional 239,712 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Kenvue by 20.2% in the 4th quarter. Janus Henderson Group PLC now owns 263,969 shares of the company's stock worth $5,640,000 after purchasing an additional 44,393 shares during the period. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE traded up $0.18 during mid-day trading on Friday, reaching $19.03. The stock had a trading volume of 26,726,491 shares, compared to its average volume of 23,182,142. The firm has a 50 day moving average price of $21.14 and a two-hundred day moving average price of $22.24. The stock has a market capitalization of $36.52 billion, a P/E ratio of 25.71, a P/E/G ratio of 2.71 and a beta of 0.83. Kenvue Inc. has a one year low of $17.15 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue's quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is presently 112.16%.

Wall Street Analyst Weigh In

KVUE has been the subject of several analyst reports. JPMorgan Chase & Co. cut their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Barclays dropped their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Tuesday, July 15th. Canaccord Genuity Group dropped their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Bank of America dropped their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Finally, Zacks Research upgraded Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $24.21.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.